FREMONT, Calif., July 14 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, today announced that it has engaged ThinkPanmure LLC., a global, growth-company investment bank, to assist the Company in identifying and evaluating strategic alternatives intended to enhance the potential of the Company's proteomic tests (OVA1(TM) and VASCLIR(TM)) and pipeline of proprietary biomarkers to maximize stockholder value. No assurances can be given that this evaluation will lead to any specific action or transaction.
"We continuously evaluate our strategic options to identify and develop prospects for maximizing value for all stockholders and look forward to working with ThinkPanmure in this regard," said Gail Page, President and Chief Executive Officer of Vermillion. "While reviewing the various alternatives, we will continue to advance our commercialization strategies, namely building marketplace awareness for our women's health, oncology, and cardiac programs which include the OVA1(TM) and VASCLIR(TM) tests."
About ThinkPanmure LLC
ThinkPanmure LLC is a research-centric institutional investment bank focused on the growth economy. ThinkPanmure LLC is dedicated to providing strategic advice, in-depth research coverage and capital to corporate clients and institutional investors interested in the knowledge economy's key growth verticals: consumer business services, healthcare, media, and technology. For more information about ThinkPanmure LLC, please visit http://www.thinkpanmure.com. Member NASD and SIPC.
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.
Forward Looking Statements
This news release contains forward-looking statements that involve significant risks and uncertainties, including the risks and uncertainties discussed in Vermillion's Form 10-K for the year ended December 31, 2007, and Vermillion's periodic reports on Form 10-Q and Form 8-K. Vermillion is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. In particular, there can be no assurance that Vermillion will enter into a strategic transaction, that, if any transaction is commenced, it will be completed or as to the value that any such transaction might have for Vermillion's stockholders. Forward-looking statements cannot be guaranteed and actual results may differ materially from Vermillion's current expectations. You are encouraged to read Vermillion's reports filed with the U.S. Securities and Exchange Commission, available at http://www.sec.gov.
|SOURCE Vermillion, Inc.|
Copyright©2008 PR Newswire.
All rights reserved